BridgeBio Pharma Revenue 2018-2026 | BBIO
BridgeBio Pharma annual/quarterly revenue history and growth rate from 2018 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- BridgeBio Pharma revenue for the quarter ending June 30, 2026 was $0.244B, a 120.39% increase year-over-year.
- BridgeBio Pharma revenue for the twelve months ending June 30, 2026 was $0.713B, a 202.39% increase year-over-year.
- BridgeBio Pharma annual revenue for 2025 was $0.502B, a 126.26% increase from 2024.
- BridgeBio Pharma annual revenue for 2024 was $0.222B, a 2285.27% increase from 2023.
- BridgeBio Pharma annual revenue for 2023 was $0.009B, a 88.02% decline from 2022.
|
BridgeBio Pharma Annual Revenue (Millions of US $) |
|
|---|---|
| 2025 | $502 |
| 2024 | $222 |
| 2023 | $9 |
| 2022 | $78 |
| 2021 | $70 |
| 2020 | $8 |
| 2019 | $41 |
|
BridgeBio Pharma Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2026-06-30 | $244 |
| 2026-03-31 | $195 |
| 2025-12-31 | $154 |
| 2025-09-30 | $121 |
| 2025-06-30 | $111 |
| 2025-03-31 | $117 |
| 2024-12-31 | $6 |
| 2024-09-30 | $3 |
| 2024-06-30 | $2 |
| 2024-03-31 | $211 |
| 2023-12-31 | $2 |
| 2023-09-30 | $4 |
| 2023-06-30 | $2 |
| 2023-03-31 | $2 |
| 2022-12-31 | $2 |
| 2022-09-30 | $0 |
| 2022-06-30 | $74 |
| 2022-03-31 | $2 |
| 2021-12-31 | $13 |
| 2021-09-30 | $2 |
| 2021-06-30 | $54 |
| 2021-03-31 | $0 |
| 2020-12-31 | $0 |
| 2020-09-30 | $8 |
| 2019-12-31 | $14 |
| 2019-09-30 | $27 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $13.352B | $0.502B |
| BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |